Buspirone controlled release - Mapi Pharma

Drug Profile

Buspirone controlled release - Mapi Pharma

Alternative Names: Buspirone ER - Mapi Pharma

Latest Information Update: 02 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mapi Pharma
  • Developer Jiangsu Nhwa Pharmaceutical; Mapi Pharma
  • Class Antidepressants; Anxiolytics; Pyrimidines; Small molecules; Spiro compounds
  • Mechanism of Action Serotonin 1A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Anxiety disorders
  • Preclinical Schizophrenia

Most Recent Events

  • 25 Oct 2017 Phase-I clinical trials in Anxiety disorders in China (PO) before October 2017 (Mapi Pharma pipeline, October 2017)
  • 25 Oct 2017 Preclinical trials in Schizophrenia in Israel (PO) before October 2017 (Mapi Pharma pipeline, October 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top